drugset / Trial / NCT02189811
Polio End-game Strategies - Poliovirus Type 2 Challenge Study
Phase 4
Completed
900 enrolled
Aga Khan University
Centers for Disease Control and Prevention · collabNational Institutes of Health (NIH) · collabWorld Health Organization · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
Poliomyelitis eradication has entered its last phase with only three remaining endemic countries, of which Pakistan is one. There hasn't been a case of wild type poliovirus 2 since 1999, and no case of wild type poliovirus 3 since November 2012. However, paralytic polio resulting from circulating strains of Sabin poliovirus type 2 have become a challenge, and reported from several areas with low population immunity to polio, including in Pakistan. This study will provide data to National Immunization Authorities in order to make strategic decisions about their polio vaccination schedules in anticipation of the global tOPV to bOPV switch and will provide data on the proposed responses to type 2 poliovirus outbreaks.
Timeline
- Start
- 2014-09
- Primary completion
- 2016-04
- Completion
- 2016-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IPV | Vaccine | — | — |
| Subject | IPV2 | Unknown | — | — |
| Subject | bOPV | Vaccine | — | — |
| Comparator | trivalent oral poliovirus vaccine | Vaccine | — | Oral |